Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
1,231,122
-
Total 13F shares
-
370,013
-
Share change
-
+330,373
-
Total reported value
-
$377,412
-
Price per share
-
$1.02
-
Number of holders
-
7
-
Value change
-
+$336,980
-
Number of buys
-
6
Institutional Holders of LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO) as of Q4 2023
As of 31 Dec 2023,
LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
370,013 shares.
The largest 7 holders included
SABBY MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, TWO SIGMA INVESTMENTS, LP, Tower Research Capital LLC (TRC), UBS Group AG, and WELLS FARGO & COMPANY/MN.
This page lists
7
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.